CClinicalTrials.gg
CompletedNCT07399691SCBPBsUpdated Feb 10, 2026

Effect of Adding Dexamethasone to Bupivacaine in Ultrasound-Guided Supraclavicular Brachial Plexus Blocks Versus Bupivacaine Alone for Upper Limb Orthopaedic Surgery

An observational study in Dexamethasone, Bupivacaine and Upper Limb Surgery, sponsored by Arsi University. Completed at 1 site in Ethiopia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Arsi University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
54
Ages
18 Years to 60 Years
Sex
All
01

Study summary

  • SCBPBs provides optimal conditions for procedures performed below the mid-upper arm (elbow, forearm, wrist, hand) due to its high success rate and ease of access.
  • Dexamethasone, when administered perineurally as an adjuvant for a supraclavicular block, demonstrated early onset of sensory and motor block, a prolonged duration of sensory and motor block, and a lower number of rescue analgesics as compared to bupivacaine alone.
  • A combination of dexamethasone and bupivacaine is paramount in adult orthopeadic patient to enhance the efficacy of pain management under ultrasound-guided supraclavicular brachial plexus block.
02

Conditions studied

  • Dexamethasone
  • Bupivacaine
  • Upper Limb Surgery

Keywords

  • dexamethasone,Bupivacaine,Analgesia,supraclavicular block
03

In context

Lead sponsor

This is the only study on the registry with Arsi University as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study included 54 patients aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular bloc

Inclusion criteria

Aged 18-60 years with ASA I and II who were scheduled for elective elbow, forearm, or hand surgery under ultrasound-guided supraclavicular block.

Exclusion criteria

Exclusion Criteria:

Patients who refused, used local anaesthetics other than bupivacaine, had multiple traumas, addition of another additive, bleeding disorders, patients diagnosed with chronic pain, cancer pain, local infection at the injection site, history of local anaesthetic allergy, patients with anxiety, and inability to comprehend or use the pain rating scale

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
54 participants (actual)
Patient registry
No

Groups and cohorts

  • Group DB

    Patients received a supraclavicular brachial plexus block with dexamethasone 2 ml (8 mg) added to 38 ml of 0.25 % bupivacaine.

    Drug: Dexamethasone 8 mg

  • Group B

    Patients received a supraclavicular brachial plexus block with 40 ml of 0.25 % bupivacaine alone.

Interventions

  • DrugDexamethasone 8 mg

    Adding 8 mg of dexamethasone to bupivacaine for ultrasound-guided supraclavicular block

06

What researchers measure

Primary outcomes

  1. The onset of sensory and motor blockade, and the duration of sensory and motor blockade in minutes.

    1. The onset of sensory: the period between injecting a study solution and losing sensation to a pinprick at every nerve distribution 2. The onset of motor block: The duration between the injection of the study solution and paresis in every nerve distribution. 3. duration of sensory: the period between the onset of a sensory block and the complete restoration of sensation. 4. Duration of motor block: the period between the onset of a motor block and the complete restoration of motor function.

    Time frame: with in the first 24hrs after procedure

Secondary outcomes

  1. postoperative pain score by a visual analogue scale

    This assesses behavioural or subjective phenomena by having the participant choose an alternative from a gradient ranging from 0 = (no pain) to 100 = worst possible pain. Based on the VAS score, 0-20 mm = no pain; 21-40 mm = mild pain; 41-60 mm = moderate pain; 61-80 mm = severe pain; and 81-100 mm = the worst pain imaginable

    Time frame: with in the first 24 hrs after procedure

  2. First analgesic request time

    The first postoperative period, when patients require pain treatment if the visual analogue score is\>4

    Time frame: With in the first 24 hrs after surgery

07

Study locations

1 site
  • Mohammed Gebi
    Āsela, Ethiopia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399691
Lead sponsor
Arsi University
Responsible party
Mohammed Gebi (lecturer at arsi university, Arsi University) — Principal investigator
First posted
Feb 10, 2026
Start date
Jan 1, 2024
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion